Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report

BACKGROUND: Pembrolizumab as immunotherapy is increasingly used in adjuvant, neoadjuvant, and standalone therapy and has been described as safe. We share an experience of lung erosion post-thoracic surgery with the use of adjuvant pembrolizumab. CASE PRESENTATION: A 65-year-old Chinese gentleman wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Leow, Lowell, Anbudurai, Manisha, Yue, Li, Tam, John Kit Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559492/
https://www.ncbi.nlm.nih.gov/pubmed/37803471
http://dx.doi.org/10.1186/s13256-023-04162-y
_version_ 1785117511552860160
author Leow, Lowell
Anbudurai, Manisha
Yue, Li
Tam, John Kit Chung
author_facet Leow, Lowell
Anbudurai, Manisha
Yue, Li
Tam, John Kit Chung
author_sort Leow, Lowell
collection PubMed
description BACKGROUND: Pembrolizumab as immunotherapy is increasingly used in adjuvant, neoadjuvant, and standalone therapy and has been described as safe. We share an experience of lung erosion post-thoracic surgery with the use of adjuvant pembrolizumab. CASE PRESENTATION: A 65-year-old Chinese gentleman with metastatic renal cell carcinoma underwent lung metastasis resection and presented with delayed onset pneumothorax while on adjuvant pembrolizumab. Failure of conservative management warranted repeat surgical intervention, and intraoperative findings showed erosion of staple lines possibly caused by poor healing associated with pembrolizumab. CONCLUSION: Adjuvant pembrolizumab may impair wound healing, including stapler line healing. Presentation of delayed pneumothorax in a post-surgical patient undergoing immunotherapy should warrant early surgical intervention.
format Online
Article
Text
id pubmed-10559492
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105594922023-10-08 Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report Leow, Lowell Anbudurai, Manisha Yue, Li Tam, John Kit Chung J Med Case Rep Case Report BACKGROUND: Pembrolizumab as immunotherapy is increasingly used in adjuvant, neoadjuvant, and standalone therapy and has been described as safe. We share an experience of lung erosion post-thoracic surgery with the use of adjuvant pembrolizumab. CASE PRESENTATION: A 65-year-old Chinese gentleman with metastatic renal cell carcinoma underwent lung metastasis resection and presented with delayed onset pneumothorax while on adjuvant pembrolizumab. Failure of conservative management warranted repeat surgical intervention, and intraoperative findings showed erosion of staple lines possibly caused by poor healing associated with pembrolizumab. CONCLUSION: Adjuvant pembrolizumab may impair wound healing, including stapler line healing. Presentation of delayed pneumothorax in a post-surgical patient undergoing immunotherapy should warrant early surgical intervention. BioMed Central 2023-10-07 /pmc/articles/PMC10559492/ /pubmed/37803471 http://dx.doi.org/10.1186/s13256-023-04162-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Leow, Lowell
Anbudurai, Manisha
Yue, Li
Tam, John Kit Chung
Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
title Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
title_full Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
title_fullStr Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
title_full_unstemmed Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
title_short Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
title_sort lung erosion following adjuvant immunotherapy with pembrolizumab: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559492/
https://www.ncbi.nlm.nih.gov/pubmed/37803471
http://dx.doi.org/10.1186/s13256-023-04162-y
work_keys_str_mv AT leowlowell lungerosionfollowingadjuvantimmunotherapywithpembrolizumabacasereport
AT anbuduraimanisha lungerosionfollowingadjuvantimmunotherapywithpembrolizumabacasereport
AT yueli lungerosionfollowingadjuvantimmunotherapywithpembrolizumabacasereport
AT tamjohnkitchung lungerosionfollowingadjuvantimmunotherapywithpembrolizumabacasereport

Ejemplares similares